ADPT
Price
$6.81
Change
-$0.11 (-1.59%)
Updated
Jan 17 closing price
Capitalization
1.01B
31 days until earnings call
BEAM
Price
$23.44
Change
+$0.04 (+0.17%)
Updated
Jan 17 closing price
Capitalization
1.94B
45 days until earnings call
Ad is loading...

ADPT vs BEAM

Header iconADPT vs BEAM Comparison
Open Charts ADPT vs BEAMBanner chart's image
Adaptive Biotechnologies
Price$6.81
Change-$0.11 (-1.59%)
Volume$1.05M
Capitalization1.01B
Beam Therapeutics
Price$23.44
Change+$0.04 (+0.17%)
Volume$950.82K
Capitalization1.94B
ADPT vs BEAM Comparison Chart
Loading...
ADPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADPT vs. BEAM commentary
Jan 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADPT is a Hold and BEAM is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 18, 2025
Stock price -- (ADPT: $6.81 vs. BEAM: $23.44)
Brand notoriety: ADPT: Notable vs. BEAM: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADPT: 76% vs. BEAM: 80%
Market capitalization -- ADPT: $1.01B vs. BEAM: $1.94B
ADPT [@Biotechnology] is valued at $1.01B. BEAM’s [@Biotechnology] market capitalization is $1.94B. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADPT’s FA Score shows that 0 FA rating(s) are green whileBEAM’s FA Score has 0 green FA rating(s).

  • ADPT’s FA Score: 0 green, 5 red.
  • BEAM’s FA Score: 0 green, 5 red.
According to our system of comparison, ADPT is a better buy in the long-term than BEAM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADPT’s TA Score shows that 4 TA indicator(s) are bullish while BEAM’s TA Score has 5 bullish TA indicator(s).

  • ADPT’s TA Score: 4 bullish, 3 bearish.
  • BEAM’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than ADPT.

Price Growth

ADPT (@Biotechnology) experienced а +4.77% price change this week, while BEAM (@Biotechnology) price change was -11.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

ADPT is expected to report earnings on Apr 30, 2025.

BEAM is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($1.94B) has a higher market cap than ADPT($1.01B). ADPT YTD gains are higher at: 13.595 vs. BEAM (-5.484). BEAM (-160.83M) and ADPT (-163.5M) have comparable annual earnings (EBITDA) . BEAM has more cash in the bank: 926M vs. ADPT (243M). ADPT has less debt than BEAM: ADPT (91.8M) vs BEAM (162M). BEAM has higher revenues than ADPT: BEAM (350M) vs ADPT (177M).
ADPTBEAMADPT / BEAM
Capitalization1.01B1.94B52%
EBITDA-163.5M-160.83M102%
Gain YTD13.595-5.484-248%
P/E RatioN/AN/A-
Revenue177M350M51%
Total Cash243M926M26%
Total Debt91.8M162M57%
TECHNICAL ANALYSIS
Technical Analysis
ADPTBEAM
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 11 days ago
90%
Bullish Trend 11 days ago
82%
Momentum
ODDS (%)
Bullish Trend 11 days ago
84%
Bearish Trend 11 days ago
89%
MACD
ODDS (%)
Bullish Trend 11 days ago
89%
Bearish Trend 11 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
80%
Bullish Trend 11 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 11 days ago
77%
Bullish Trend 11 days ago
83%
Advances
ODDS (%)
Bullish Trend 16 days ago
81%
Bullish Trend 12 days ago
81%
Declines
ODDS (%)
Bearish Trend 19 days ago
87%
Bearish Trend 17 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 11 days ago
85%
Bullish Trend 11 days ago
74%
Aroon
ODDS (%)
Bullish Trend 11 days ago
75%
N/A
View a ticker or compare two or three
Ad is loading...
ADPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TRZAX46.280.28
+0.61%
T. Rowe Price Value Z
VMCCX52.14N/A
N/A
Virtus KAR Mid-Cap Core C
FLMAX9.43N/A
N/A
Meeder Muirfield Adviser
AFOIX18.48N/A
N/A
Alger Mid Cap Focus I
SUTCX15.80N/A
N/A
AB Sustainable US Thematic C